Simpex Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.50 Cr
as on 24-10-2024
- Paid Up Capital ₹ 2.50 Cr
as on 24-10-2024
- Company Age 27 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 9.95 Cr
as on 24-10-2024
- Satisfied Charges ₹ 25.42 Cr
as on 24-10-2024
- Revenue 47.12%
(FY 2023)
- Profit 6781.97%
(FY 2023)
- Ebitda 127.61%
(FY 2023)
- Net Worth 64.42%
(FY 2023)
- Total Assets -0.42%
(FY 2023)
About Simpex Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 Cr and a paid-up capital of Rs 2.50 Cr.
The company currently has active open charges totaling ₹9.95 Cr. The company has closed loans amounting to ₹25.42 Cr, as per Ministry of Corporate Affairs (MCA) records.
Piyush Singh, Naresh Santhanam, and Ajay Mishra serve as directors at the Company.
- CIN/LLPIN
U33112DL1997PTC085657
- Company No.
085657
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Mar 1997
- Date of AGM
15 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Simpex Pharma Private Limited offer?
Simpex Pharma Private Limited offers a wide range of products and services, including Pharma Ingredients & Raw Materials, Antipyretic and Analgesic API.
Who are the key members and board of directors at Simpex Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Piyush Singh  | Director | 02-Jan-2020 | Current |
| Naresh Santhanam | Director | 15-Feb-2010 | Current |
| Ajay Mishra | Director | 06-Apr-2010 | Current |
Financial Performance of Simpex Pharma.
Simpex Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 47.12% increase. The company also saw a substantial improvement in profitability, with a 6781.97% increase in profit. The company's net worth Soared by an impressive increase of 64.42%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Simpex Pharma?
In 2023, Simpex Pharma had a public holding of 6.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 10 Jan 2022 | ₹9.95 Cr | Open |
Corporation Bank Creation Date: 14 Apr 2011 | ₹5.42 Cr | Satisfied |
Corporation Bank Creation Date: 21 Oct 2009 | ₹10.00 Cr | Satisfied |
How Many Employees Work at Simpex Pharma?
Simpex Pharma has a workforce of 148 employees as of Apr 24, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Simpex Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Simpex Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
